Q-omics provides the consensus-scored RENBP profile across patient tissues and cancer cell-line models. RENBP expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RENBP is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, RENBP protein abundance shows 22,193 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where RENBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RENBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RENBP survival associations across molecular data types. RENBP RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RENBP RNA expression–survival associations across cancer types. High RENBP expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, LUAD, SCLC and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RENBP RNA expression.
This table summarizes RENBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RENBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RENBP shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, THCA, STAD and LIHC. The HNSC box plot shows higher RENBP RNA expression in tumor versus normal tissue (log2 FC = +1.421, t-test p < 0.001).
This table shows molecular features associated with RENBP in patient tissues and cancer cell lines. In patient samples, RENBP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RENBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SKIN.
